Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02966314 · ClinicalTrials.gov registry record · Phase 4
Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT02966314 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 12 participants.
The verdict
NCT02966314, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The overall hospitalizations for a diagnosis of angioedema doubled from the year 2000 to 2009. Although some of the cases represented hereditary angioedema or ace-inhibitor induced angioedema, the majority of episodes were idiopathic. Idiopathic Angioedema (IAE) can be life- threatening especially when affecting tissues within the respiratory tract. No clear guidelines exist for management of this important condition for clinicians. Current therapies typically include avoidance of potential triggers and use of medications either for prophylaxis or for acute events, such as antihistamines, corticosteroids, and epinephrine. There remains a critical need for therapeutic options to provide more effective prophylaxis.
Interventions
- DRUG Placebos
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2020-01-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02966314
The ClinicalTrials.gov registry entry for NCT02966314 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT02966314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02966314 about?
NCT02966314 is a clinical study titled "Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy". The overall hospitalizations for a diagnosis of angioedema doubled from the year 2000 to 2009. Although some of the cases represented hereditary angioedema or ace-inhibitor induced angioedema, the majority of episodes were idiopathic. Idiopathic Angioedema (IAE) can be life- threatening especially w...
What is the current status of trial NCT02966314?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2017-03-30. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT02966314?
The interventions under investigation include: Placebos (DRUG), Omalizumab (DRUG).
Who is sponsoring clinical trial NCT02966314?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.